Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Frid | M | 52 |
Felicitex Therapeutics, Inc.
 Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
| Mark Benthin | M | - |
Viihealth, Inc.
 Viihealth, Inc. Advertising/Marketing ServicesCommercial Services Viihealth, Inc. provides digital medical solutions for pharmaceutical and life sciences companies. The company was founded by Sunny Verma and Mark Benthin and is headquartered in Bethlehem, PA. | - |
| Maria Vilenchik | M | 55 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
| Sunny Verma | M | - |
Viihealth, Inc.
Viihealth, Inc. Advertising/Marketing ServicesCommercial Services Viihealth, Inc. provides digital medical solutions for pharmaceutical and life sciences companies. The company was founded by Sunny Verma and Mark Benthin and is headquartered in Bethlehem, PA. | - |
| Alex Shlyankevich | M | 63 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 7 years |
| Mel Prenovitz | M | - |
New View Surgical, Inc.
 New View Surgical, Inc. Medical SpecialtiesHealth Technology New View Surgical, Inc. develops a proprietary surgical imaging system for laproscopic surgery. The company was founded by Mel Prenovitz, Art McKinley and Jesse Plouffe and is headquartered in Boston, MA. | - |
| Bryce Klontz | M | - |
New View Surgical, Inc.
New View Surgical, Inc. Medical SpecialtiesHealth Technology New View Surgical, Inc. develops a proprietary surgical imaging system for laproscopic surgery. The company was founded by Mel Prenovitz, Art McKinley and Jesse Plouffe and is headquartered in Boston, MA. | - |
| Yuriy Gankin | M | 58 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 12 years |
| Douglas Moore | M | 67 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 2 years |
| Nancy Briefs | F | - |
New View Surgical, Inc.
New View Surgical, Inc. Medical SpecialtiesHealth Technology New View Surgical, Inc. develops a proprietary surgical imaging system for laproscopic surgery. The company was founded by Mel Prenovitz, Art McKinley and Jesse Plouffe and is headquartered in Boston, MA. | - |
| Scott Flora | M | 59 |
New View Surgical, Inc.
New View Surgical, Inc. Medical SpecialtiesHealth Technology New View Surgical, Inc. develops a proprietary surgical imaging system for laproscopic surgery. The company was founded by Mel Prenovitz, Art McKinley and Jesse Plouffe and is headquartered in Boston, MA. | - |
| Mark H. Schneider | M | - |
New View Surgical, Inc.
New View Surgical, Inc. Medical SpecialtiesHealth Technology New View Surgical, Inc. develops a proprietary surgical imaging system for laproscopic surgery. The company was founded by Mel Prenovitz, Art McKinley and Jesse Plouffe and is headquartered in Boston, MA. | - |
| Marc Duey | M | 68 |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | 10 years |
| Michael Kody | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Valeria Povolotsky | M | - |
Felicitex Therapeutics, Inc.
Felicitex Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Felicitex Therapeutics, Inc. is a pre-clinical stage oncology drug development company developing therapies against cancer and diabetes. It operates through the Felicitex Business and TraMeta segments. The Felicitex Business segment handles the design and patents of small molecules and related methods to selectively disrupt dormant cancer cells in a manner that is specific to the disease and tissue context. The TarMeta segment built a drug discovery platform for small molecule inhibitors targeting cancer. The company was founded by Maria Vilenchik and Michael Frid on May 4, 2012 and is headquartered in Natick, MA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 15 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Arthur T. Healey
- Personal Network
